Cannabix Technologies Inc. (USOTC:BLOZF) (CSE:BLO) (TG:8CT), together with Omega Laboratories Inc., announced that a peer-reviewed validation study confirming the accuracy of their marijuana breath testing method has been published by Oxford University Press in the Journal of Analytical Toxicology.
The study, titled “Simultaneous Analysis of Δ9 THC, Δ8 THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit,” details the successful validation of Omega’s laboratory method for detecting multiple cannabinoids in breath samples collected using Cannabix’s Breath Collection Unit (BCU) and proprietary breath cartridges.
The publication represents a significant milestone in the development of cannabis breath testing technology, particularly for applications in workplace safety, law enforcement, and other safety-sensitive environments. Unlike traditional blood or urine tests that often detect past use, the breath-based system is designed to identify recent cannabis consumption — typically within a window of 15 minutes to four hours.
Strategic partnership and validation milestone
Cannabix and Omega entered into a strategic partnership in May 2024 to refine both the Breath Collection Unit hardware and the associated laboratory testing methodology. Over a 20-month collaboration, Cannabix enhanced the BCU’s design and collection safeguards, while Omega optimized a highly sensitive analytical method capable of detecting trace cannabinoid levels in breath using LC-MS/MS technology.
The resulting validation study, conducted in accordance with ANSI/ASB Standard 036 (First Edition 2019) guidelines, confirms the method’s reliability, sensitivity, and reproducibility. Publication in the Journal of Analytical Toxicology, the official journal of the Society of Forensic Toxicologists (SOFT) and The International Association of Forensic Toxicologists (TIAFT), underscores that the research met rigorous peer-review standards.
“This new publication reinforces the effectiveness of using breath to detect recent drug use,” said Bill Corl, CEO of Omega. “This achievement further demonstrates our expertise in forensic toxicology and our commitment to providing advanced testing solutions.”
Key findings from the study
The validation introduces several important advancements in breath-based cannabis detection:
- Simultaneous quantification of multiple cannabinoids, including Δ9-THC, Δ8-THC, cannabidiol (CBD), and cannabinol (CBN), from breath aerosols.
- A streamlined laboratory method offering improved sensitivity and precision compared to earlier approaches.
- Confirmation that breath samples collected with the Cannabix kit remain stable for up to seven days.
- Additional evidence showing that THC concentration trends in breath correlate with established blood-based metabolism patterns.
Because of the technical complexity of detecting THC at extremely low concentrations, analysis is conducted in a laboratory setting using LC-MS/MS instrumentation. Breath samples collected roadside, at workplaces, or in clinical environments are sent to Omega’s lab for confirmatory testing.
The collection protocol includes an ambient air sample followed by simultaneous A and B cartridge samples. The A sample is screened first; if presumptively positive, the B sample undergoes confirmatory analysis. Ambient air testing helps rule out environmental contamination.
Advancing non-invasive cannabis testing
While alcohol breath testing is well established, cannabis detection presents scientific challenges due to the low concentration of THC in exhaled breath. Omega’s decades of experience in high-sensitivity drug detection — including hair analysis — has contributed to refining a method capable of reliably identifying same-day THC use.
Rav Mlait, CEO of Cannabix Technologies, stated, “The peer reviewed article publication in the prestigious Journal of Analytical Toxicology is a significant milestone for Cannabix and its shareholders. I commend the dedicated efforts of both the Cannabix and Omega teams in advancing our breath-based technology to help improve public safety.”
Cannabix is now working to scale manufacturing of its Breath Collection Units and collection kits. The BCU incorporates several safeguards designed to ensure reproducible sampling, including breath pressure and volume monitoring, dual-cartridge collection, and ambient air validation.
Marketing agreement extension
Separately, effective March 3, 2026, Cannabix extended an arm’s-length digital marketing agreement with Black Swan Solutions Inc., operating as VHLA Media. Under the one-month engagement, VHLA Media will provide social media development and online campaign services for a fee of US$8,000. The agreement may be renewed upon mutual consent. No securities will be issued as compensation, and to the company’s knowledge, VHLA Media does not hold any Cannabix securities.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) develops marijuana and alcohol breath testing technologies for workplace, law enforcement, and related applications. Its Marijuana Breath Test (MBT) targets delta-9 THC in breath to identify recent cannabis use. The company also develops the BreathLogix autonomous alcohol screening device.
About Omega Laboratories, Inc.
Omega Laboratories, headquartered in Mogadore, Ohio, with a facility in Ontario, Canada, provides laboratory-based drug testing services to more than 6,000 clients worldwide. With over 25 years of experience, Omega specializes in detecting drugs of abuse using hair, oral fluid, urine, and breath samples. The company also offers technical solutions including a multilingual electronic Custody & Control Form system and a toxicology-focused Laboratory Information Management System (LIMS).